Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 4/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2357987 | 0.89 | KCNN4 (0.30) | — | |
| Hydrochloric Acid SCHEMBL2244902 | 0.80 | KCNN4 (0.33) | — | |
| Hydrochloric Acid SCHEMBL29205648 | 0.80 | KIF11 (0.33) | KIF11 | |
| Hydrochloric Acid SCHEMBL2245745 | 0.79 | ALDH1A1 (0.37) | — | |
| Hydrochloric Acid SCHEMBL2245514 | 0.79 | MEN1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL2358777 | 0.78 | CYP2B6 (0.37) | — | |
| Hydrochloric Acid SCHEMBL29205650 | 0.77 | KCNN4 (0.33) | KIF11CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL2240353 | 0.76 | MEN1 (0.32) | KIF11CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL2245303 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL2245337 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308936-A1 | METHOD FOR PRODUCING ALPHA-OLEFIN OLIGOMER COMPOSITION | IDEMITSU KOSAN CO.,LTD. (JP) | 2024-09-19 | — | — | US | disclosed |
| EP-4385972-A1 | METHOD FOR PRODUCING ALPHA-OLEFIN OLIGOMER COMPOSITION | Idemitsu Kosan Co.,Ltd. (JP) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023017779-A1 | METHOD FOR PRODUCING α-OLEFIN OLIGOMER COMPOSITION | 出光興産株式会社 | 2023-02-16 | — | — | WO | disclosed |
| US-20110207977-A1 | METHOD FOR PRODUCING A-OLEFIN OLIGOMER, A-OLEFIN OLIGOMER, AND LUBRICATING OIL COMPOSITION | IDEMITSU KOSAN CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2351722-A1 | METHOD FOR PRODUCING -OLEFIN OLIGOMER, -OLEFIN OLIGOMER, AND LUBRICATING OIL COMPOSITION | Idemitsu Kosan Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207977-A1 | METHOD FOR PRODUCING A-OLEFIN OLIGOMER, A-OLEFIN OLIGOMER, AND LUBRICATING OIL COMPOSITION | MOGAT2, OSBP, OXER1 | CHRM2 2791/4885CHRM1 2409/4885CHRM3 1421/4885 |
| US-20240308936-A1 | METHOD FOR PRODUCING ALPHA-OLEFIN OLIGOMER COMPOSITION | OXER1, AMY1A, MACF1 | CHRM2 1572/4885CHRM1 707/4885CHRM3 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.